CRLBF - How To Invest In Marijuana Stocks 2023
2023-04-02 18:54:46 ET
Are You Ready To Invest In Marijuana Stocks?
Cannabis investing refers to the act of investing in companies that are involved in the production, distribution, and sale of cannabis products. This includes all things marijuana, hemp, and CBD with the easiest bare-to-entry being marijuana stocks for cannabis investing. As the cannabis industry continues to grow and evolve, investing in it has become increasingly popular. Here are a few things to keep in mind if you’re interested in cannabis investing:
- Understand the legal landscape: Before investing in the cannabis industry, it’s important to understand the legal landscape surrounding cannabis in the country or region where you’re investing. In some places, cannabis is legal for medical and/or recreational use, while in others it remains illegal.
- Research the company: As with any investment, it’s important to thoroughly research the company before investing. Look at the company’s financials, management team, products, and competitive landscape.
- Consider the risks: While the cannabis industry has a lot of potential for growth, it’s also a relatively new and untested market. There are regulatory risks, market risks, and other uncertainties to consider.
- Diversify your portfolio: It’s always a good idea to diversify your portfolio, and looking for marijuana stocks to buy should be no different. Don’t put all your money into one cannabis company. But spread your investments across several companies in the sector.
- Learn How To Invest And Trade: If you’re new to investing, or if you’re not familiar with cannabis stocks, it may be a good idea to consult with someone who does before making any investment decisions.
Ultimately, investing in marijuana stocks can be a high-risk, high-reward opportunity. As with any investment, it’s important to do your due diligence when looking for marijuana stocks to watch .
Top Marijuana Stocks To Watch Now
Trulieve Cannabis Corp.
Trulieve Cannabis Corp. together with its subsidiaries operates as a medical cannabis company. The company cultivates and produces products in-house. Plus they distribute their products to Trulieve branded stores (dispensaries) in Florida.
As well as through home delivery. Recently the company announced the opening of a medical marijuana dispensary in Palatka, FL.
[Read More] 2 Top Marijuana Stocks For Cannabis Investing 2023
Words From The Company
“Trulieve is proud to expand access to medical cannabis in Florida by opening a new dispensary in Palatka,” said Trulieve’s Chief Executive Officer Kim Rivers. “We’re committed to being active in the communities we serve, as well as providing high-quality cannabis and exceptional customer experiences to
[Read More] Will Cannabis Stocks Rally In April? 3 To Watch This Month
Cresco Labs Inc.
Cresco Labs Inc. together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. Recently the company reported its Q4 and full-year 2022 results.
Fiscal Year 2022 Financial Highlights
- Record revenue of $843 million, an increase of 3% year-over-year; excluding California distribution operations exited in 2021, adjusted revenues grew 6% year-over-year.
- Record branded unit volume of 61 million, up 37% year-over-year2.
- Record retail transactions of 4.6 million, up 15% year-over-year.
- Adjusted gross profit1 of $418 million, or 50% of revenue.
- Adjusted EBITDA1 of $174 million, or 21% of revenue.
- Net loss of $215 million for the full year included $141 million of one-time impairment charges.
- Generated positive operating cash flow of $19 million for the full year and ended the year with $122 million of cash, cash equivalents, and restricted cash.
Q4 2022 Financial Highlights
- Fourth quarter revenue of $200 million, down 8% year-over-year.
- Branded unit volume of 17 million, up 24% year-over-year2.
- Retail transactions of 1.2 million, up 4% year-over-over.
- Growth from increased unit sales and retail transactions was offset by price compression across the industry.
- Adjusted gross profit1 of $90 million, or 45% of revenue.
- Fourth quarter adjusted EBITDA1 of $31 million, or 15% of revenue.